Structural basis for therapeutic intervention of uPA/uPAR system

Current Drug Targets

Volumn 12, Issue 12, 2011, Pages 1729-1743

  Ngo, Jacky Chi Ki ^a   Jiang, Longguang ^b   Lin, Zhonghui ^b   Yuan, Cai ^b   Chen, Zhuo ^b   Zhang, Xu ^b   Yu, Haiyang ^c   Wang, Jundong ^c   Lin, Lin ^d   Huang, Mingdong ^b,d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER   (China)

^c FUZHOU UNIVERSITY   (China)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Crystal structures; Inhibitors; SMB; uPA; uPAR

Indexed keywords

ARGININE; BENZYLSULFONYL D SER GLY 4 AMIDINOBENZYLAMIDE; BLOOD CLOTTING FACTOR 7A; GEMCITABINE; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN; SIGNAL PEPTIDE; TRYPSIN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN;

ARTICLE; BINDING SITE; CELL ADHESION; CRYSTAL STRUCTURE; DRUG DESIGN; HUMAN; IN VIVO STUDY; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 80054080464     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011797635911     Document Type: Article

References (97)

1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase- type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72(1): 1-22.
2. Blasi F. Carmeliet uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3(12): 932-43.
3. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003; 9(19): 1499-528.
4. Dupont DM, Madsen JB, Kristensen T, et al. Biochemical properties of plasminogen activator inhibitor-1. Front Biosci 2009; 14: 1337-61.
5. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5(10): 1135-42.
6. Jean-Claude J, Newman KM, Li H, Gregory AK, Tilson MD. Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms. Surgery 1994; 116(2): 472-8.
7. Busso N, Peclat V, Van Ness K, et al. Exacerbation of antigen- induced arthritis in urokinase-deficient mice. J Clin Invest 1998; 102(1): 41-50. Current Drug Targets, 2011, Vol. 12, No. 12 1741.
8. Gveric D, Hanemaaijer R, Newcombe J, et al. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 2001; 124(Pt 10): 1978-88.
9. Almholt K, Lund LR, Rygaard J, et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005; 113(4): 525-32.
10. Nielsen BS, Rank F, Illemann M, Lund LR, Dano K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer 2007; 120(10): 2086-95.
11. Pappot H, Hoyer-Hansen G, Ronne E, et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997; 33(6): 867-72.
12. Pedersen N, Schmitt M, Ronne E, et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993; 92(5): 2160-7.
13. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91(10): 869-74.
14. Stephens RW, Pedersen AN, Nielsen HJ, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997; 43(10): 1868-76.
15. Brunner N, Nielsen HJ, Hamers M, et al. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 1999; 107(1): 160-7.
16. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60(3): 636-43.
17. Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007; 25(1): 33-9.
18. Kanno Y, Kuroki A, Minamida M, et al. The absence of uPAR attenuates insulin-induced vascular smooth muscle cell migration and proliferation. Thromb Res 2008; 123(2): 336-41.
19. Spraggon G, Phillips C, Nowak UK, et al. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 1995; 3(7): 681-91.
20. Hansen AP, Petros AM, Meadows RP, et al. Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry 1994; 33(16): 4847-64.
21. Barinka C, Parry G, Callahan J, et al. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol 2006; 363(2): 482-95.
22. Zeslawska E, Jacob U, Schweinitz A, et al. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors. J Mol Biol 2003; 328(1): 109-18.
23. Nienaber VL, Davidson D, Edalji R, et al. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Structure 2000; 8(5): 553-63.
24. Katz BA, Mackman R, Luong C, et al. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol 2000; 7(4): 299-312.
25. Rockway TW, Nienaber V, Giranda VL. Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr Pharm Des 2002; 8(28): 2541-58.
26. Rockway TW, Giranda VL. Inhibitors of the proteolytic activity of urokinase type plasminogen activator. Curr Pharm Des 2003; 9(19): 1483-98.
27. Schechter I, Berger A. On the size of the active site in proteases. I. Papain Biochem Biophys Res Commun 1967; 27: 157-62.
28. Katz BA, Elrod K, Luong C, et al. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site. J Mol Biol 2001; 307(5): 1451-86.
29. Mackman RL, Katz BA, Breitenbucher JG, et al. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator. J Med Chem 2001; 44(23): 3856-71.
30. Katz BA, Luong C, Ho JD, et al. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA). J Mol Biol 2004; 344(2): 527-47.
31. Nienaber V, Wang J, Davidson D, Henkin J. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. J Biol Chem 2000; 275(10): 7239-48.
32. Wendt MD, Rockway TW, Geyer A, et al. Identification of novel binding interactions in the development of potent, selective 2- naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution. J Med Chem 2004; 47(2): 303-24.
33. Wendt MD, Geyer A, McClellan WJ, et al. Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8- disubstituted 2-naphthamidine urokinase inhibitors. Bioorg Med Chem Lett 2004; 14(12): 3063-8.
34. Sperl S, Mueller MM, Wilhelm OG, et al. The uPA/uPA receptor system as a target for tumor therapy. Drug News Perspectives 2001; 14(7): 401-11.
35. Setyono-Han B, Sturzebecher J, Schmalix WA, et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 2005; 93(4): 779-86.
36. Kunzel S, Schweinitz A, Reissmann S, Sturzebecher J, Steinmetzer T. 4-amidinobenzylamine-based inhibitors of urokinase. Bioorg Med Chem Lett 2002; 12(4): 645-8.
37. Banke IJ, Arlt MJ, Pennington C, et al. Increase of anti-metastatic efficacy by selectivity- but not affinity-optimization of synthetic serine protease inhibitors. Biol Chem 2003; 384(10-11): 1515-25.
38. Schweinitz A, Steinmetzer T, Banke IJ, et al. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004; 279(32): 33613-22.
39. Krowarsch D, Cierpicki T, Jelen F, Otlewski J. Canonical protein inhibitors of serine proteases. Cell Mol Life Sci 2003; 60(11): 2427-44.
40. Hansen M, Wind T, Blouse GE, et al. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. J Biol Chem 2005; 280(46): 38424-37.
41. Zhao G, Yuan C, Wind T, et al. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. J Struct Biol 2007; 160(1): 1-10.
42. Petersen HH, Hansen M, Schousboe SL, Andreasen PA. Localization of epitopes for monoclonal antibodies to urokinase- type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme. Eur J Biochem 2001; 268(16): 4430-9.
43. Andersen LM, Wind T, Hansen HD, Andreasen PA. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue. Biochem J 2008; 412(3): 447-57.
44. Menear K. Progress towards the discovery of orally active thrombin inhibitors. Curr Med Chem 1998; 5(6): 457-68.
45. Frederickson M, Callaghan O, Chessari G, et al. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem 2008; 51(2): 183-6.
46. Jiang LG, Yu HY, Yuan C, et al. Crystal Structures of 2- Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Plasminogen Activator. Chin J Struct Chem 2009; 28(11): 1427-32.
47. West CW, Adler M, Arnaiz D, et al. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA). Bioorg Med Chem Lett 2009; 19(19): 5712-5.
48. Heinemann V, Ebert MP, Pinter T, et al. Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer. J Clin Oncol 2010; 28(15 Suppl): 4060.
49. Behrendt N. The urokinase receptor (uPAR) and the uPAR- associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biol Chem 2004; 385(2): 103-36.
50. Pass J, Jogi A, Lund IK, et al. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo. Thromb Haemost 2007; 97(6): 1013-22.
51. Bauer TW, Liu W, Fan F, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c- Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005; 65(17): 7775-81.
52. Kobayashi H, Sugino D, She MY, et al. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis. Eur J Biochem 1998; 253(3): 817-26.
53. Quax PH, Lamfers ML, Lardenoye JH, et al. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation 2001; 103(4): 562-9.
54. Muehlenweg B, Assfalg-Machleidt I, Parrado SG, et al. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site. J Biol Chem 2000; 275(43): 33562-6.
55. Magdolen V, Burgle M, de Prada NA, et al. Cyclo19,31[D-Cys19]- uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol Chem 2001; 382(8): 1197-205.
56. Burgle M, Koppitz M, Riemer C, et al. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol Chem 1997; 378(3-4): 231-7.
57. Ploug M, Ostergaard S, Gardsvoll H, et al. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001; 40(40): 12157-68.
58. Knor S, Sato S, Huber T, et al. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging 2008; 35(1): 53-64.
59. Sato S, Kopitz C, Schmalix WA, et al. High-affinity urokinase- derived cyclic peptides inhibiting urokinase/urokinase receptor- interaction: effects on tumor growth and spread. FEBS Lett 2002; 528(1-3): 212-6.
60. Jorgensen TJ, Gardsvoll H, Dano K, Roepstorff P, Ploug M. Dynamics of urokinase receptor interaction with Peptide antagonists studied by amide hydrogen exchange and mass spectrometry. Biochemistry 2004; 43(47): 15044-57.
61. Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA 1994; 91(15): 7129-33.
62. Rosenberg S. New developments in the urokinase-type plasminogen activator system. Expert Opin Ther Targets 2001; 5(6): 711-722.
63. Llinas P, Le Du MH, Gardsvoll H, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005; 24(9): 1655-63.
64. Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006; 311(5761): 656-9.
65. Huai Q, Zhou A, Lin L, et al. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol 2008; 15(4): 422-3.
66. Lin L, Gardsvoll H, Huai Q, Huang M, Ploug M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem 2010; 285(14): 10982-92.
67. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007; 450(7172): 1001-9.
68. Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380(6569): 41-6.
69. Reuning U, Sperl S, Kopitz C, et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 2003; 9(19): 1529-1543.
70. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol 2007; 177(5): 927-39.
71. Hillig T, Engelholm LH, Ingvarsen S, et al. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. J Biol Chem 2008; 283(22): 15217-23.
72. Caiolfa VR, Zamai M, Malengo G, et al. Monomer dimer dynamics and distribution of GPI-anchored uPAR are determined by cell surface protein assemblies. J Cell Biol 2007; 179(5): 1067-82.
73. Gardsvoll H, Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J Biol Chem 2007; 282(18): 13561-72.
74. Gardsvoll H, Dano K, Ploug M. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis. J Biol Chem 1999; 274(53): 37995-8003.
75. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25(33): 5287-312.
76. Gils A, Stassen JM, Nar H, et al. Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb Haemost 2002; 88(1): 137-43.
77. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 2003; 10(7): 541-4.
78. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9(5): 714-24.
79. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000; 12(5): 613-20.
80. Kiyan J, Kiyan R, Haller H, Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR- beta. EMBO J 2005; 24(10): 1787-97.
81. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002; 1(5): 445-57.
82. Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 1999; 147(1): 89-104.
83. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273(5281): 1551-5.
84. Xue W, Mizukami I, Todd RF 3rd, Petty HR. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res 1997; 57(9): 1682-9.
85. Pluskota E, Soloviev DA, Plow EF. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood 2003; 101(4): 1582-90.
86. Tang CH, Hill ML, Brumwell AN, Chapman HA, Wei Y. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins. J Cell Sci 2008; 121(Pt 22): 3747-56.
87. Silvestri I, Longanesi CI, Franco P, et al. Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression. Int J Cancer 2002; 102(6): 562-71.
88. Wei Y, Eble JA, Wang Z, Kreidberg JA, Chapman HA. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell 2001; 12(10): 2975-86.
89. Carriero MV, Franco P, Gargiulo L, et al. Inhibition of receptor- dependent urokinase signaling by specific Ser to Glu substitutions. Biol Chem 2002; 383(1): 107-13.
90. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63(7): 1684-95.
91. Zhang F, Tom CC, Kugler MC, et al. Distinct ligand binding sites in integrin alpha3beta1 regulate matrix adhesion and cell-cell contact. J Cell Biol 2003; 163(1): 177-88.
92. Simon DI, Wei Y, Zhang L, et al. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 2000; 275(14): 10228-34.
93. Degryse B, Resnati M, Czekay RP, Loskutoff DJ, Blasi F. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem 2005; 280(26): 24792-803.
94. Chaurasia P, Aguirre-Ghiso JA, Liang OD, et al. A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J Biol Chem 2006; 281(21): 14852-63.
95. Chaurasia P, Mezei M, Zhou MM, Ossowski L. Computer aided identification of small molecules disrupting uPAR/alpha5beta1-integrin interaction: a new paradigm for metastasis prevention. PLoS One 2009; 4(2): e4617.
96. Chen Z, Lin L, Huai Q, Huang M. Challenges for drug discovery - a case study of urokinase receptor inhibition. Comb Chem High Throughput Screen 2009; 12(10): 961-7.
97. Nykjaer A, Kjoller L, Cohen RL, et al. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 1994; 269(41): 25668-76.